Table 1.
Taxane-induced peripheral neuropathy incidence in phase II/III clinical trials of metastatic breast cancer
| Study | Population (no.) | Taxane | Dosage and schedule | Sensory neuropathy, % | ||
|---|---|---|---|---|---|---|
| Grade 2 | Grade 3 | Grade 4 | ||||
| Albain et al. [81] | Metastatic, previously treated (521) | Paclitaxel | 175 mg/m2 q3w | 18 | 4–5 | <1 |
| Andersson et al. [82] | Metastatic or locally advanced, previously treated (139) | Docetaxel | 100 mg/m2 q3w | 19 | 31 | 0 |
| Fountzilas et al. [83] | Metastatic, previously treated (131) | Paclitaxel (plus carboplatin) | 175 mg/m2 q3w | NR | 5a (grade 3 or higher) | |
| Metastatic, previously treated (134) | Docetaxel | 75 mg/m2 q3w | NR | 0a (grade 3 or higher) | ||
| Metastatic, previously treated (133) | Paclitaxel | 80 mg/m2 weekly | NR | 8a (grade 3 or higher) | ||
| Gradishar et al. [17] | Metastatic, previously treated (229) | nab-Paclitaxel | 260 mg/m2 q3w | NR | 10 | 0 |
| Metastatic, previously treated (225) | Paclitaxel | 175 mg/m2 q3w | NR | 2 | 0 | |
| Gradishar et al. [16] | Metastatic first-line (76) | nab-Paclitaxel | 300 mg/m2 q3w | NR | 21 | 0 |
| Metastatic first-line (76) | nab-Paclitaxel | 100 mg/m2 qw | NR | 9 | 0 | |
| Metastatic first-line (74) | nab-Paclitaxel | 150 mg/m2 qw | NR | 22 | 0 | |
| Metastatic first-line (74) | Docetaxel | 100 mg/m2 q3w | NR | 12 | 0 | |
| Miles et al. [84] | Metastatic or locally advanced, previously treated (231) | Docetaxel | 100 mg/m2 q3w | NR | 2 (grade 3 or higher) | |
| Miller et al. [85] | Metastatic or locally advanced, previously treated (346) | Paclitaxel | 90 mg/m2 weekly for 3 of 4 weeks | NR | 17 | <1 |
| Rivera et al. [28] | Metastatic or locally advanced, previously treated (59) | Docetaxel | 75 mg/m2 q3w | NR | 10 (grade 3 or higher) | |
| Metastatic or locally advanced, previously treated (59) | Docetaxel | 35 mg/m2 weekly every 3 of 4 weeks | NR | 5 (grade 3 or higher) | ||
| Seidman et al. [29] | Metastatic, previously treated (225) | Paclitaxel | 175 mg/m2 q3w | 21 | 12 | 0 |
| Metastatic, previously treated (346) | Paclitaxel | 80–100 mg/m2 weekly | 21 | 24–30 | <1 | |
| Valero et al. [86] | Metastatic, previously treated (131) | Docetaxel | 100 mg/m2 q3w | 58 (grades 1–4); 3 (grade 3 or higher) | ||
| Metastatic, previously treated (131) | Docetaxel (plus carboplatin) | 75 mg/m2 q3w | 46 (grades 1–4); 1 (grade 3 or higher) | |||
| Winer et al. [30] | Metastatic, previously treated (158) | Paclitaxel | 175 mg/m2 q3w | 57 (grades 1–4); 7 (grade 3 or higher) | ||
| Metastatic, previously treated (156) | Paclitaxel | 210 mg/m2 q3w | 73 (grades 1–4); 19 (grade 3 or higher) | |||
| Metastatic, previously treated (155) | Paclitaxel | 250 mg/m2 q3w | 83 (grades 1–4); 33 (grade 3 or higher) | |||
NR not reported, q3w every 3 weeks, qw every week
a Sensory versus motor not delineated